SLC5A2 and hydrops fetalis: Thus, SGLT2 inhibitors have emerged as a promising class of drugs in the treatment of AHF, since these drugs have shown to improve cardiovascular outcomes, reduce HF hospitalizations, and improve symptoms and quality of life measures in patients with AHF.